Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers

References

• Patel NT, Steuer CE. PARP-1 inhibitors and their emerging role in the treatment of lung cancer; 2015.
   Google Scholar
• Farmer H, McCabe H, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Harrision D, Gravells P, Thompson R, Bryant HE. Poly(ADP-Ribose) glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - function in genome maintenance and relevance of inhibitors for anti-cancer therapy. Front Mol Biosci. 2020;7:191.
   PubMed Web of Science ®Google Scholar
• Chan CY, Tan KV, Cornelissen B. PARP inhibitors in cancer diagnosis and therapy. Clin Cancer Res. 2021;27(6):1585–1594. doi:10.1158/1078-0432.CCR-20-2766
   PubMed Web of Science ®Google Scholar
• Wang X, Zeng X, Li D, et al. PARP inhibitors in small cell lung cancer: the underlying mechanisms and clinical implications. Biomed Pharmacother. 2022;153:113458. doi:10.1016/j.biopha.2022.113458
   PubMed Web of Science ®Google Scholar
• Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7(6):596–609. doi:10.1158/2159-8290.CD-16-1337
   PubMed Web of Science ®Google Scholar
• Jonsson P, Bandlamudi C, Cheng ML, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571(7766):576–579. doi:10.1038/s41586-019-1382-1
   PubMed Web of Science ®Google Scholar
• Paul I, Savage KI, Blayney JK, et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol. 2011;224(4):564–574. doi:10.1002/path.2925
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S, Bajrami I, Friboulet L, et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene. 2013;32(47):5377–5387. doi:10.1038/onc.2013.311
   PubMed Web of Science ®Google Scholar
• Jiang G, Zhang S, Yazdanparast A, et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016;17(Suppl 7):13–15. doi:10.1186/s12864-016-2911-z
   PubMedGoogle Scholar
• Remon J, Besse B, Leary A, et al. Somatic and Germline BRCA 1 and 2 mutations in advanced NSCLC from the SAFIR02-lung trial. JTO Clin Res Rep. 2020;1(3):100068.
   PubMedGoogle Scholar
• Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–1426. doi:10.1016/S0140-6736(16)00004-0
   PubMed Web of Science ®Google Scholar
• Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination–related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2(2):1–13.
   Google Scholar
• Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069. doi:10.1038/nature07423
   PubMed Web of Science ®Google Scholar
• Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7(7):428–430. doi:10.1038/nchembio.573
   PubMed Web of Science ®Google Scholar
• Vendetti FP, Lau A, Schamus S, Conrads TP, O’Connor MJ, Bakkenist CJ. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6(42):44289. doi:10.18632/oncotarget.6247
   PubMedGoogle Scholar
• Hall AB, Newsome D, Wang Y, et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014;5(14):5674–5685. doi:10.18632/oncotarget.2158
   PubMedGoogle Scholar
• Toledo LI, Murga M, Zur R, et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011;18(6):721–727. doi:10.1038/nsmb.2076
   PubMed Web of Science ®Google Scholar
• O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547–560. doi:10.1016/j.molcel.2015.10.040
   PubMed Web of Science ®Google Scholar
• Jette NR, Radhamani S, Arthur G, et al. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells. Br J Cancer. 2019;121(7):600–610. doi:10.1038/s41416-019-0565-8
   PubMed Web of Science ®Google Scholar
• Dillon L, Miller T. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 2014;15(1):65–79. doi:10.2174/1389450114666140106100909
   PubMed Web of Science ®Google Scholar
• Sargazi S, Saravani R, Zavar Reza J, et al. Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells. Iran Biomed J. 2019;23(5):312–323. doi:10.29252/ibj.23.5.2
   PubMedGoogle Scholar
• Sargazi S, Saravani R, Zavar Reza J, et al. Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid. EXCLI J. 2019;18:485–498. doi:10.17179/excli2019-1098
   PubMed Web of Science ®Google Scholar
• Sargazi S, Kooshkaki O, Zavar Reza J, et al. Mild antagonistic effect of Valproic acid in combination with AZD2461 in MCF-7 breast cancer cells. Med J Islam Repub Iran. 2019;33:29. doi:10.34171/mjiri.33.29
   PubMedGoogle Scholar
• Mullane SA, Werner L, Guancial EA, et al. Expression levels of DNA damage repair proteins are associated with overall survival in platinum treated advanced urothelial carcinoma. Clin Genitourin Cancer. 2016;14(4):352. doi:10.1016/j.clgc.2015.12.029
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158. doi:10.1126/science.aam7344
   PubMed Web of Science ®Google Scholar
• Kummar S, Chen A, Parchment RE, et al. Advances in using PARP inhibitors to treat cancer. BMC Med. 2012;10:10. doi:10.1186/1741-7015-10-10
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active Poly(ADP-Ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728–2737.
   PubMed Web of Science ®Google Scholar
• Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15(23):7277–7290. doi:10.1158/1078-0432.CCR-09-1245
   PubMed Web of Science ®Google Scholar
• Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor. Clin Cancer Res. 2012;18(2):510–523. doi:10.1158/1078-0432.CCR-11-1973
   PubMed Web of Science ®Google Scholar
• Reck M, Blais N, Juhasz E, et al. Smoking history predicts sensitivity to PARP inhibitor veliparib in patients with advanced non–small cell lung cancer. J Thoracic Oncol. 2017;12(7):1098–1108. doi:10.1016/j.jtho.2017.04.010
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Novello S, Guclu SZ, et al. Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter Phase III study. J Clin Oncol. 2021;39(32):3633. doi:10.1200/JCO.20.03318
   PubMed Web of Science ®Google Scholar
• Lesueur P, Chevalier F, Austry JB, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8(40):69105–69124. doi:10.18632/oncotarget.19079
   PubMedGoogle Scholar
• Albert JM, Cao C, Kwang WK, et al. Inhibition of Poly(ADP-Ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13(10):3033–3042. doi:10.1158/1078-0432.CCR-06-2872
   PubMed Web of Science ®Google Scholar
• Cristea MC, Miao J, Argiris A, et al. SWOG S1206: a dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(15_suppl):8537.
   Web of Science ®Google Scholar
• Kozono DE, Stinchcombe TE, Salama JK, et al. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021;159:56–65. doi:10.1016/j.lungcan.2021.06.028
   PubMed Web of Science ®Google Scholar
• de Haan R, van den Heuvel MM, van Diessen J, et al. Phase I and pharmacologic study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer. Clin Cancer Res. 2021;27(5):1256–1266. doi:10.1158/1078-0432.CCR-20-2551
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa1801005
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa1810865
   PubMed Web of Science ®Google Scholar
• Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers. 2020;12(6):1502. doi:10.3390/cancers12061502
   PubMed Web of Science ®Google Scholar
• Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–693. doi:10.1158/2159-8290.CD-17-0226
   PubMed Web of Science ®Google Scholar
• Barber GN. STING: infection, inflammation and cancer. Nat Rev Immunol. 2015;15(12):760. doi:10.1038/nri3921
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019;9(1):1853.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Raparia K, et al. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer. Clin Lung Cancer. 2019;20(2):88–96.e6. doi:10.1016/j.cllc.2018.09.008
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Wang X, Alessi JV, et al. Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160. doi:10.1001/jamaoncol.2022.1981
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Recondo G, Spurr LF, et al. Impact of DNA Damage Response and Repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non–small cell lung cancer. Clin Cancer Res. 2020;26(15):4135–4142. doi:10.1158/1078-0432.CCR-19-3529
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Thara E, Awad MM, et al. JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer. Cancer. 2022;128(1):65. doi:10.1002/cncr.33885
   PubMed Web of Science ®Google Scholar
• Clarke JM, Patel JD, Robert F, et al. Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: a phase 1 dose escalation study. Lung Cancer. 2021;161:180–188. doi:10.1016/j.lungcan.2021.09.004
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum‐based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(25):2969. doi:10.1200/JCO.2016.66.9861
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031. doi:10.1056/NEJMoa1910231
   PubMed Web of Science ®Google Scholar
• Jamil S, Stoica C, Hackett TL, Duronio V. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle. 2010;9(14):2843. doi:10.4161/cc.9.14.12354
   PubMed Web of Science ®Google Scholar
• Mattoo AR, Joun A, Milburn Jessup J. Repurposing of mTOR complex inhibitors attenuates Mcl-1 and sensitizes to PARP inhibition. Mol Cancer Res. 2019;17(1):42–53. doi:10.1158/1541-7786.MCR-18-0650
   PubMed Web of Science ®Google Scholar
• Ibrahim YH, García-García C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–1047. doi:10.1158/2159-8290.CD-11-0348
   PubMed Web of Science ®Google Scholar
• Wang D, Li C, Zhang Y, et al. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol. 2016;142(3):548–556. doi:10.1016/j.ygyno.2016.07.092
   PubMed Web of Science ®Google Scholar
• Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integr. 2013;4(1):5. doi:10.1186/2041-9414-4-5
   PubMedGoogle Scholar
• Bizzaro F, Fuso Nerini I, Taylor MA, et al. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. J Hematol Oncol. 2021;14(1):1–7. doi:10.1186/s13045-021-01196-x
   PubMed Web of Science ®Google Scholar
• Pfaäffle HN, Wang M, Gheorghiu L, et al. EGFR-activating mutations correlate with a fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. Cancer Res. 2013;73(20):6254–6263. doi:10.1158/0008-5472.CAN-13-0044
   PubMed Web of Science ®Google Scholar
• Mahdi H, Hafez N, Doroshow D, et al. Ceralasertib-mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (Olaparib Combinations). JCO Precis Oncol. 2021;5(5):1432–1442. doi:10.1200/PO.20.00439
   Google Scholar
• Krebs MG, Lopez J, El-Khoueiry A, et al. Abstract CT026: phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res. 2018;78(13_Supplement):CT026–CT026. doi:10.1158/1538-7445.AM2018-CT026
   Web of Science ®Google Scholar
• Mittra A, Coyne GHO, Do KT, et al. Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors. J Clin Oncol. 2019;37(15_suppl):3067.
   Web of Science ®Google Scholar
• Hafez N, Soliman HH, Fu S, et al. Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: a phase II study of cediranib in combination with olaparib in advanced solid tumors. J Clin Oncol. 2020;38(15_suppl):1077.
   Web of Science ®Google Scholar
• Garcia-Campelo R, Arrieta O, Massuti B, et al. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): a multicenter, randomized phase II study (GOAL). Lung Cancer. 2020;150:62–69. doi:10.1016/j.lungcan.2020.09.018
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Arrieta O, Giménez-Capitán A, et al. BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. JTO Clin Res Rep. 2021;2(3):100113. doi:10.1016/j.jtocrr.2020.100113
   PubMedGoogle Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. doi:10.1038/nature14664
   PubMed Web of Science ®Google Scholar
• Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–1116. doi:10.1038/ng.2405
   PubMed Web of Science ®Google Scholar
• Tlemsani C, Takahashi N, Pongor L, et al. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. Sci Transl Med. 2021;13(578). doi:10.1126/scitranslmed.abc7488
   PubMed Web of Science ®Google Scholar
• Sen T, Tong P, Wang J, Byers LA. Abstract LB-132: proteomic profiling identifies ATM expression level as a predictive biomarker to ATR and PARP inhibition in small cell lung cancer (SCLC). Cancer Res. 2016;76(14_Supplement):LB–132. doi:10.1158/1538-7445.AM2016-LB-132
   Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798–811. doi:10.1158/2159-8290.CD-12-0112
   PubMed Web of Science ®Google Scholar
• Woll P, Gaunt P, Steele N, et al. P1.07-015 STOMP: a UK national cancer research network randomised, double blind, multicentre Phase II trial of olaparib as maintenance therapy in SCLC. J Thoracic Oncol. 2017;12(1):S704–S705. doi:10.1016/j.jtho.2016.11.926
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Dahlberg SE, Sica GL, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37(3):222–229. doi:10.1200/JCO.18.00264
   PubMed Web of Science ®Google Scholar
• Byers LA, Bentsion D, Gans S, et al. Veliparib in combination with carboplatin and etoposide in patients with treatment-Naïve extensive-stage small cell lung cancer: a phase 2 randomized study. Clin Cancer Res. 2021;27(14):3884–3895. doi:10.1158/1078-0432.CCR-20-4259
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18(4):1138–1145. doi:10.1158/1078-0432.CCR-11-2059
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36(23):2386–2394. doi:10.1200/JCO.2018.77.7672
   PubMed Web of Science ®Google Scholar
• Lazzari C, Gregorc V, Bulotta A, Dottore A, Altavilla G, Santarpia M. Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. Transl Lung Cancer Res. 2018;7(S4):S329–S333. doi:10.21037/tlcr.2018.12.02
   PubMedGoogle Scholar
• Ndrew A, Urrisi TT, Onald R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. J Med. 1999;340(4):265–271.
   Google Scholar
• Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 2010;327(23):1618–1624.
   Google Scholar
• Warde P, Payne D, Ahn SH. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. Gut and Liver. 2016;10(6):890–895. doi:10.5009/gnl15573
   PubMedGoogle Scholar
• Tariq S, Kim SY, Monteiro de Oliveira Novaes J, Cheng H. Update 2021: management of Small Cell Lung Cancer. Lung. 2021;199(6):579–587. doi:10.1007/s00408-021-00486-y
   PubMed Web of Science ®Google Scholar
• Rathod S, Jeremic B, Dubey A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer. 2019;110:110–119. doi:10.1016/j.ejca.2019.01.003
   PubMed Web of Science ®Google Scholar
• Powell C, Mikropoulos C, Kaye SB, et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev. 2010;36(7):566–575. doi:10.1016/j.ctrv.2010.03.003
   PubMed Web of Science ®Google Scholar
• Cardnell RJ, Feng Y, Diao L, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013;19(22):6322–6328. doi:10.1158/1078-0432.CCR-13-1975
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Zhang G, Deng X, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014;3(6):1579–1594. doi:10.1002/cam4.317
   PubMed Web of Science ®Google Scholar
• Laird JH, Lok BH, Ma J, et al. Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts. Clin Cancer Res. 2018;24(20):5143–5152. doi:10.1158/1078-0432.CCR-18-0401
   PubMed Web of Science ®Google Scholar
• Esposito G, Palumbo G, Carillio G, et al. Immunotherapy in Small Cell Lung Cancer. Cancers. 2020;12(9):2522. doi:10.3390/cancers12092522
   PubMed Web of Science ®Google Scholar
• MacKenzie KJ, Carroll P, Martin CA, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548(7668):461–465. doi:10.1038/nature23449
   PubMed Web of Science ®Google Scholar
• Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466–470. doi:10.1038/nature23470
   PubMed Web of Science ®Google Scholar
• Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. CGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19(1):1–16. doi:10.1186/s12943-020-01247-w
   PubMed Web of Science ®Google Scholar
• Ablasser A, Goldeck M, Cavlar T, et al. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013;498(7454):380–384. doi:10.1038/nature12306
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal. 2012;5(214). doi:10.1126/scisignal.2002521
   PubMed Web of Science ®Google Scholar
• Shen J, Zhao W, Ju Z, et al. PARPI triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANEss. Cancer Res. 2019;79(2):311–319. doi:10.1158/0008-5472.CAN-18-1003
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–3720. doi:10.1158/1078-0432.CCR-16-3215
   PubMed Web of Science ®Google Scholar
• Robillard L, Nguyen M, Loehr A, et al. Abstract 3650: preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model. Cancer Res. 2017;77(13_Supplement):3650. doi:10.1158/1538-7445.AM2017-3650
   Google Scholar
• Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9(5):646–661. doi:10.1158/2159-8290.CD-18-1020
   PubMed Web of Science ®Google Scholar
• Thomas A, Vilimas R, Trindade C, et al. Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a Phase II study. J Thoracic Oncol. 2019;14(8):1447–1457. doi:10.1016/j.jtho.2019.04.026
   PubMed Web of Science ®Google Scholar
• Krebs M, Ross K, Kim S, et al. P1.15-004 an open-label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): results in Patients with Relapsed SCLC. J Thoracic Oncol. 2017;12(11):S2044–S2045. doi:10.1016/j.jtho.2017.09.1040
   Web of Science ®Google Scholar
• Friedlander M, Meniawy T, Markman B, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(9):1306–1315. doi:10.1016/S1470-2045(19)30396-1
   PubMed Web of Science ®Google Scholar
• Doerr F, George J, Schmitt A, et al. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Sci Rep. 2017;7(1):1–16. doi:10.1038/s41598-017-15840-5
   PubMedGoogle Scholar
• Sen T, Tong P, Stewart CA, et al. CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib. Cancer Res. 2017;77(14):3870–3884. doi:10.1158/0008-5472.CAN-16-3409
   PubMed Web of Science ®Google Scholar
• Hamilton E, Falchook GS, Wang JS, et al. Abstract CT025: phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: dose escalation. Cancer Res. 2019;79(13_Supplement):CT025–CT025. doi:10.1158/1538-7445.AM2019-CT025
   Web of Science ®Google Scholar
• Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2022;33(2):129–142. doi:10.1016/j.annonc.2021.11.005
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. doi:10.1016/S0140-6736(20)32714-8
   PubMed Web of Science ®Google Scholar
• Betti M, Casalone E, Ferrante D, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 2017;405:38–45. doi:10.1016/j.canlet.2017.06.028
   PubMed Web of Science ®Google Scholar
• Panou V, Gadiraju M, Wolin A, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36(28):2863–2871. doi:10.1200/JCO.2018.78.5204
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–416. doi:10.1038/ng.3520
   PubMed Web of Science ®Google Scholar
• Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264–269. doi:10.1158/0008-5472.CAN-14-1008
   PubMed Web of Science ®Google Scholar
• Cantini L, Pecci F, Murrone A, et al. Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: a single center experience with systematic review and meta-analysis. Lung Cancer. 2020;146:318–326. doi:10.1016/j.lungcan.2020.06.024
   PubMed Web of Science ®Google Scholar
• Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668–672. doi:10.1038/ng.855
   PubMed Web of Science ®Google Scholar
• Srinivasan G, Sidhu GS, Williamson EA, et al. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017;80(4):861–867.
   PubMed Web of Science ®Google Scholar
• Borchert S, Wessolly M, Schmeller J, et al. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro. BMC Cancer. 2019;19(1):1–12. doi:10.1186/s12885-019-5314-0
   PubMedGoogle Scholar
• Gabano E, Pinton G, Balzano C, et al. Unsymmetric cisplatin-based Pt(IV) conjugates containing a PARP-1 inhibitor pharmacophore tested on malignant pleural mesothelioma cell lines. Molecules. 2021;26(16):4740.
   PubMed Web of Science ®Google Scholar
• Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1549–1565. doi:10.1158/2159-8290.CD-18-0804
   Web of Science ®Google Scholar
• Ghafoor A, Mian I, Wagner C, et al. Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene. JTO Clin Res Rep. 2021;2(10):100231. doi:10.1016/j.jtocrr.2021.100231
   PubMedGoogle Scholar
• Passiglia F, Bironzo P, Righi L, et al. A prospective Phase II single-arm study of niraparib plus dostarlimab in patients with advanced non–small-cell lung cancer and/or malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: rationale and study design. Clin Lung Cancer. 2021;22(1):e63–e66. doi:10.1016/j.cllc.2020.07.014
   PubMed Web of Science ®Google Scholar
• Fennell DA, King A, Mohammed S, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. Lancet Respir Med. 2021;9(6):593–600. doi:10.1016/S2213-2600(20)30390-8
   PubMed Web of Science ®Google Scholar
• Pastorino S, Yoshikawa Y, Pass HI, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. J Clin Oncol. 2018;36(35):3485–3494.
   Web of Science ®Google Scholar
• Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34(5–6):360–394. doi:10.1101/gad.334516.119
   PubMed Web of Science ®Google Scholar
• Gravells P, Grant E, Smith KM, James DI, Bryant HE. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase. DNA Repair. 2017;52:81–91. doi:10.1016/j.dnarep.2017.02.010
   PubMed Web of Science ®Google Scholar
• Pillay N, Tighe A, Nelson L, et al. DNA replication vulnerabilities render ovarian cancer cells sensitive to Poly(ADP-Ribose) glycohydrolase inhibitors. Cancer Cell. 2019;35(3):519–533.e8. doi:10.1016/j.ccell.2019.02.004
   PubMed Web of Science ®Google Scholar
• Chen SH, Yu X. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies. Sci Adv. 2019;5(4):eaav4340. doi:10.1126/sciadv.aav4340
   PubMed Web of Science ®Google Scholar
• Leenus M, Tzuling C, Dominic IJ, et al. Abstract 1943: PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition. Cancer Res. 2018;78(13_Supplement):1943. doi:10.1158/1538-7445.AM2018-1943
   Web of Science ®Google Scholar
• Sasaki Y, Fujimori H, Hozumi M, et al. Dysfunction of Poly (ADP-Ribose) glycohydrolase induces a synthetic lethal effect in dual specificity phosphatase 22-deficient lung cancer cells. Cancer Res. 2019;79(15):3851–3861. doi:10.1158/0008-5472.CAN-18-1037
   PubMed Web of Science ®Google Scholar
• Noll A, Illuzzi G, Amé JC, Dantzer F, Schreiber V. PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency. Cancer Cell Int. 2016;16(1):53. doi:10.1186/s12935-016-0333-2
   PubMedGoogle Scholar
• Karpova Y, Johnson SJ, Bordet G, et al. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes. Biomed Pharmacother. 2022;153:113504. doi:10.1016/j.biopha.2022.113504
   PubMed Web of Science ®Google Scholar
• Jain A, Agostini LC, McCarthy GA, et al. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Res. 2019;79(17):4491–4502. doi:10.1158/0008-5472.CAN-18-3645
   PubMed Web of Science ®Google Scholar
• Nakadate Y, Kodera Y, Kitamura Y, Tachibana T, Tamura T, Koizumi F. Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint. Biochem Biophys Res Commun. 2013;441(4):793–798. doi:10.1016/j.bbrc.2013.10.134
   PubMed Web of Science ®Google Scholar
• Gravells P, Neale J, Grant E, et al. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: a comparison with the PARP1/2/3 inhibitor olaparib. DNA Repair. 2018;61:25–36. doi:10.1016/j.dnarep.2017.11.004
   PubMed Web of Science ®Google Scholar
• Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer. 2021;7(10):958–970. doi:10.1016/j.trecan.2021.05.004
   PubMed Web of Science ®Google Scholar
• Fennell DA, Porter C, Lester J, et al. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): a multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine. 2022;52:101595. doi:10.1016/j.eclinm.2022.101595
   PubMedGoogle Scholar
• Riess JW, Redman MW, Wheatley-Price P, et al. A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). J Clin Oncol. 2021;39(15_suppl):9024. doi:10.1200/JCO.2021.39.15_suppl.9024
   Google Scholar
• Farkkila A, Gulhan D, Casado J, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11(1):1459. doi:10.1038/s41467-020-15315-8
   PubMed Web of Science ®Google Scholar
• Karzai F, VanderWeele D, Madan R, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6(1):141. doi:10.1186/s40425-018-0463-2
   PubMedGoogle Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20. doi:10.1021/nn900002m
   PubMed Web of Science ®Google Scholar
• Alotaibi BS, Buabeid M, Ibrahim NA, et al. Potential of nanocarrier-based drug delivery systems for brain targeting: a current review of literature. Int J Nanomed. 2021;16:7517–7533. doi:10.2147/IJN.S333657
   PubMed Web of Science ®Google Scholar
• Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual AM. Active targeted nanoparticles for delivery of Poly(ADP-ribose) polymerase (PARP) inhibitors: a preliminary review. Int J Mol Sci. 2021;22(19):10319. doi:10.3390/ijms221910319
   PubMed Web of Science ®Google Scholar